FOI 23/388

Dear

Thank you for your request of 31 May under the Freedom of Information Act. We apologise for the delay in reply. You requested:

> *I seek data about the first 40 batches of Pfizer authorised and distributed in the United Kingdom including EJ0553, since 2nd December 2020.*
>
> 1. *Please provide a list in chronological order of these batch date authorisations including Batch EJ0553*
> 2. *Please show the total dose numbers for each of these batches*

For question 1, please see the table listing the first 40 batch authorisations as requested. Please note that batches may subsequently have been used in the UK in a different order to the list of authorisations and dates provided below.

n	Batch number	NIBSC certificate issued on:
1	EJ0553	2.12.20
2	EJ0724	7.12.20
3	EJ1688	7.12.20
4	EL0141	7.12.20
5	EL0739	14.12.20
6	EK1768	17.12.20
7	EK4243	18.12.20
8	EK4237	21.12.20
9	EE8492	21.12.20
10	EE8493	21.12.20
11	EN3924	15.1.21
12	EN1185 **	19.1.21
13	EL7834	21.1.21
14	EK4244	25.1.21
15	EK4176	25.1.21
16	EJ6790	26.1.21
17	EL8713	01.02.21
18	ER1741	11.2.21
19	ER1749	23.2.21
20	ER7934	24.2.21
21	EM4965	26.2.21
22	ER9449	19.3.21
23	EW4109	22.3.21
24	EW2245	1.4.21
25	ET8885	23.4.21

26	EY5456	04.5.21
27	EW3143	6.5.21
28	FA5843	07.5.21
29	FA1027	21.5.21
30	FC8289	26.5.21
31	FC9001	06.6.21
32	FD5613	08.6.21
33	FE1510	17.6.21
34	FD8813	25.6.21
35	FF3319	29.6.21
36	FE3380	07.7.21
37	FF2153	12.7.21
38	FE8087	13.7.21
39	FF8222	27.7.21
40	FG3712	30.07.21

** Please note, this batch was tested in two parts. The second certificate (supplementary) was issued to cover the entire batch which was made available to the UK. The Supplementary certificate supersedes the first one.

For question 2, information about the total dose numbers for each of these batches, whilst the MHRA holds some information relevant to your request, we have determined that it is exempt under Section 41 (S41) and Section 43 (S43) of the Freedom of Information Act. S41 applies when the information has been provided to a public authority in confidence. This is an absolute exemption, and no consideration of the public interest is required, except to state that we would consider the release of this information to be an actionable breach of confidence.

S43 applies when disclosure would be likely to prejudice the commercial interests of a third party. This is a qualified exemption and requires a consideration of the public interest. While there is a public interest in disclosure where this would demonstrate transparency and accountability, on this occasion this does not outweigh the public interest in maintaining the exemption and protecting against commercial harm to a third-party.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: info@mhra.gov.uk
Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:
Information Commissioner's Office
Wycliffe House

Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely
MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU